This report, Kalorama’s Cell and Gene Deals and Market Analysis, tracks the dealmaking and market opportunity in cell and gene therapy. The report includes specific details of 1000+ deals from 2022-2023. A lot of attention is being given to the areas related to cell and gene therapy (CGT) recently. Kalorama’s CGT deals amounted to a staggering $40 billion in 2022. Understanding the deals that have been made, who is making them, and what the specific details are is critical to understanding how to take advantage of the market opportunity in one of the fastest-growing pharma markets.
EXAMPLE CHART: Total Number of VC/ Private Funding Deals by Month, Jan 2021-Mar 2023
Kalorama’s report is designed to provide companies entering or already in this market information on the deals that will shape future growth and competition.
The following is just some of the information in this report:
Specific details of 1000+ Cell and Gene Therapy Deals from 2022-2023
Venture Capital/Private Funding Round Amounts, By Quarter
Chronological Trends Presented in Multiple Categories (VC, M&A, Other Areas)
Deals by Type – Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation
Most Active Deal-Making Companies, by Type of Deal (Acquisition/Merger/ Strategic Investment, Overall Deals, Collaborations)
Regional Breakdown of Dealmaking [North America, Europe, APAC, Rest of World] (%)
Most Frequent Types of Deals, by Quarter, by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; and Manufacturing, Supply Chain] (Total number)
Estimated Market Forecasts for Cell and Gene Therapies by Type (Gene Therapy, Cell Therapy)
Estimated Market Forecasts by Region (North America, EU, APAC, Other)
Estimated Market Forecasts for CGT by Disease Category (Oncology, Other)
EXAMPLE CHART: Average Merger/Acquisition Amount, By Quarter [Q1 2021-Q1 2023] ($M)
No report published by a major market research publisher has tackled the Cell and Gene Therapy dealmaking space as it exists in 2023 in a more comprehensive fashion. As Cell and Gene Therapy is a highly competitive marketplace, hundreds of companies are referenced in this report.
While the concepts of gene therapy and cell therapy have been investigated for decades, there were major challenges in the early years. Through incremental progress, and the gradual introduction of enabling tools such as CRISPR and next-generation sequencing (NGS), cell and gene therapy has emerged into a highly active area. There are now many approved therapies with proven track records.
As the new tools have lowered the barriers to entry for the industry, over 1,500 companies have been created or have become involved.
Table of Contents
Chapter 1: Executive Summary
Introduction
$40.2 Billion in Funding During 2022
Figure 1-1: Total Deals per Month, April 2021-March 2023 (Total count)
Figure 1-2: Total Deals per Month by Type, Apr 2021-Mar 2023 [VC/ Private, IPO/FPO/SPAC; and All Other Deals] (Total count)
Quarterly Funding Amounts
Table 1-1: Total Quarterly Funding, by Type, Q1 2021-Q4 2021 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] ($M)
Table 1-2: Total Quarterly Funding, by Type, Q1 2022-Q1 2023 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] ($M)
Figure 1-3: Total Quarterly Funding, Q1 2021- Q1 2023 ($M)
Figure 1-4: Total Quarterly Funding, by Type, Q1 2021-Q1 2023 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] ($M)
Quarterly Funding Category Shares, Q1 2021 Through Q1 2023
Table 1-3: Total Quarterly Funding Share, by Type, 2021 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
Table 1-4: Total Quarterly Funding Share, by Type, Q1 2022-Q1 2023 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
Figure 1-5: Q1 2022 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
Figure 1-6: Q2 2022 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
Figure 1-7: Q3 2022 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
Figure 1-8: Q4 2022 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
Figure 1-9: Q1 2023 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
Quarterly Deal Counts by Category, Q1 2021 – Q1 2023
Table 1-5: Quarterly Count of Deals, By 2021 Quarter, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number) (%)
Table 1-6: Quarterly Count of Deals, by Quarter Q1 2022-Q1 2023, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number) (%)
Growth in Collaborations, Manufacturing/Supply Chain Deals, Licensing, Distribution/ Co-Marketing Highlight Activity in Cell and Gene Therapy
Figure 1-10: Most Frequent Types of Deals, by Quarter, by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; and Manufacturing, Supply Chain] (Total number)
A Look at Less Frequent CGT Deal Types
Figure 1-11: Lower Frequency Deal Types, by Quarter, by Category [Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number)
